Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCT Nuvectis Pharma, Inc.

Closed 02-11 16:00:00 EST

8.78

+0.04

+0.46%

盘后8.78

+0.000.00%

19:03 EST

High8.85	Low8.12	Vol105.00K
Open8.85	D1 Closing8.74	Amplitude8.35%
Mkt Cap224.90M	Tradable Cap127.63M	Total Shares25.61M
T/O890.40K	T/O Rate0.72%	Tradable Shares14.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCT","market":"US","secType":"STK","nameCN":"Nuvectis Pharma, Inc.","latestPrice":8.78,"timestamp":1770843600000,"preClose":8.74,"halted":0,"volume":105002,"hourTrading":{"tag":"盘后","latestPrice":8.78,"preClose":8.78,"latestTime":"19:03 EST","volume":3046,"amount":26745.2,"timestamp":1770854627174,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.004576659038901504,"floatShares":14536600,"shares":25614896,"eps":-1.359454,"marketStatus":"Closed","change":0.04,"latestTime":"02-11 16:00:00 EST","open":8.85,"high":8.85,"low":8.12,"amount":890395.0145820001,"amplitude":0.083524,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.359454,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770886800000},"marketStatusCode":5,"adr":0,"listingDate":1638334800000,"exchange":"NASDAQ","adjPreClose":8.74,"postHourTrading":{"tag":"盘后","latestPrice":8.78,"preClose":8.78,"latestTime":"19:03 EST","volume":3046,"amount":26745.2,"timestamp":1770854627174,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.472249,"impliedVol":1.1683,"impliedVolPercentile":0.4622},"requestUrl":"/m/hq/s/NVCT/wiki","defaultTab":"wiki","newsList":[{"id":"2610892955","title":"Nuvectis Pharma Q4 EPS $(0.31), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2610892955","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610892955?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:13","pubTimestamp":1770819199,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is a 13.89 percent increase over losses of $(0.36) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50540929/nuvectis-pharma-q4-eps-0-31-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT"],"gpt_icon":0},{"id":"2610932732","title":"Nuvectis Pharma Inc. FY25 net loss attributable to common shareholders widens to USD 28.87 million, up 52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610932732","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610932732?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:32","pubTimestamp":1770813167,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc. reported its financial results for the full year ended December 31, 2025. Research and development expenses for the period totaled USD 18.15 million, while general and administrative expenses amounted to USD 9.42 million. The company recorded a finance income of USD 1.13 million. Operating loss for the year was USD 27.57 million, and net loss stood at USD 26.44 million. The total net loss attributable to common shareholders was USD 28.87 million, with basic and diluted net loss per common share at USD 1.32. Shareholders' equity as of December 31, 2025, was USD 18.41 million, and total liabilities and shareholders' equity reached USD 31.71 million. During the year, Nuvectis Pharma Inc. made significant progress in its NXP900 development program. The company highlighted advancements in the Phase 1b monotherapy study of NXP900, an oral small molecule inhibitor targeting the SRC Family of Kinases, including SRC and YES1. Management noted that these developments lay the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLbn2Q5c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2610932720","title":"Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2610932720","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610932720?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:30","pubTimestamp":1770813000,"startTime":"0","endTime":"0","summary":"FORT LEE, N.J., Feb.  11, 2026  (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (\"Nuvectis\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of innovat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/11/3236181/0/en/Nuvectis-Pharma-Inc-Reports-2025-Financial-Results-and-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2592994042","title":"Nuvectis Pharma Announces the Initiation of the Phase 1B Study of Nxp900 in Combination With Osimertinib in Patients With Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592994042?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUADYJSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2592992590","title":"Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2592992590","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592992590?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972800,"startTime":"0","endTime":"0","summary":"The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung c","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3206848/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Study-of-NXP900-in-Combination-with-Osimertinib-in-Patients-with-NSCLC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2586912473","title":"Nuvectis Pharma Hosts Virtual Meeting on NXP900 Phase 1b Program in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2586912473","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586912473?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:00","pubTimestamp":1764075624,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc. will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025, at 8:00 AM ET to discuss the NXP900 Phase 1b Program in advanced solid tumors, including its combination with osimertinib in non-small cell lung cancer. The event will feature experts including Dr. Alexander Spira and Dr. Asier Uncita-Broceta, and will cover key preclinical and clinical data and development strategies for NXP900. A live Q&A session will follow, and a replay will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 25, 2025, and is solely responsible for the information contain","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDLbF7M1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","NVCT","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2584541889","title":"Buy Rating for Nuvectis Pharma’s NXP900 Driven by Promising Efficacy and Development Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2584541889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584541889?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:55","pubTimestamp":1763484925,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Nuvectis Pharma, with a price target of $17.00. Naz Rahman h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-nuvectis-pharmas-nxp900-driven-by-promising-efficacy-and-development-progress-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-nuvectis-pharmas-nxp900-driven-by-promising-efficacy-and-development-progress-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","NVCT"],"gpt_icon":0},{"id":"2581026333","title":"Nuvectis Pharma Executives Make Bold Moves with Major Stock Purchases!","url":"https://stock-news.laohu8.com/highlight/detail?id=2581026333","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581026333?lang=en_us&edition=fundamental","pubTime":"2025-11-07 10:07","pubTimestamp":1762481264,"startTime":"0","endTime":"0","summary":"New insider activity at Nuvectis Pharma ( ($NVCT) ) has taken place on November 6, 2025. In a series of significant transactions, key figures at Nu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/nuvectis-pharma-executives-make-bold-moves-with-major-stock-purchases-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/nuvectis-pharma-executives-make-bold-moves-with-major-stock-purchases-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2581009353","title":"Director Matthew L. Kaplan Acquires Common Shares of Nuvectis Pharma Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009353","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581009353?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:01","pubTimestamp":1762434068,"startTime":"0","endTime":"0","summary":"Matthew L. Kaplan, Director of Nuvectis Pharma Inc., reported the acquisition of common shares of Nuvectis Pharma Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL2BLPq4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Matthew L. Kaplan Acquires Common Shares of Nuvectis Pharma Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2581770198","title":"Maxim Group Reaffirms Their Buy Rating on Nuvectis Pharma (NVCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581770198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581770198?lang=en_us&edition=fundamental","pubTime":"2025-11-06 01:36","pubTimestamp":1762364161,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Naz Rahman reiterated a Buy rating on Nuvectis Pharma yesterday and set a price target of $17.00. According to TipRanks, Rahman...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-nuvectis-pharma-nvct-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-nuvectis-pharma-nvct-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"gpt_icon":0},{"id":"2581279711","title":"Nuvectis Pharma Reports Progress in Oncology Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2581279711","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581279711?lang=en_us&edition=fundamental","pubTime":"2025-11-05 13:05","pubTimestamp":1762319124,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc. ( ($NVCT) ) has released its Q3 earnings. Here is a breakdown of the information Nuvectis Pharma, Inc. presented to its inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nuvectis-pharma-reports-progress-in-oncology-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nuvectis-pharma-reports-progress-in-oncology-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2065732104.USD","BK4097","NVCT","PRGS"],"gpt_icon":0},{"id":"2580627756","title":"Analysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO) and Nuvectis Pharma (NVCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580627756","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580627756?lang=en_us&edition=fundamental","pubTime":"2025-11-04 23:31","pubTimestamp":1762270278,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alpha Teknova (TKNO – Research Report) and Nuvectis ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alpha-teknova-tkno-and-nuvectis-pharma-nvct-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alpha-teknova-tkno-and-nuvectis-pharma-nvct-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4121","BK4581","TKNO","BK4137","XBI","BK4585","BK4539","LU0128526141.USD","LABU","XLV","BK4588","LU0029874061.USD","HCSG","NVCT"],"gpt_icon":0},{"id":"2580873298","title":"Nuvectis Pharma Q3 EPS $(0.44) Misses $(0.25) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2580873298","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580873298?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:30","pubTimestamp":1762263038,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.25) by 73.91 percent. This is a 83.33 percent decrease over losses of $(0.24) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48618467/nuvectis-pharma-q3-eps-0-44-misses-0-25-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT"],"gpt_icon":0},{"id":"2580734428","title":"BRIEF-Nuvectis Pharma Q3 EPS USD -0.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2580734428","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580734428?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:15","pubTimestamp":1762262146,"startTime":"0","endTime":"0","summary":"BRIEF-Nuvectis Pharma Q3 EPS USD -0.44\n\n\nNov 04 (Reuters) - Nuvectis Pharma Q3 operating income USD -7.794 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLX4C862A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2580739647","title":"Nuvectis Pharma Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2580739647","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580739647?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:37","pubTimestamp":1762259856,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Q3 net loss widensOverviewNuvectis Q3 net loss widens to $7.5 mln, driven by milestone and study costsCash position improves to $35.4 mln, supported by public offering and ATM facility","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG0LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2580973986","title":"Nuvectis Pharma Inc: Cash Runway Expected to Support Company's Operations Into 3Q-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2580973986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580973986?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:30","pubTimestamp":1762259456,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG0AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2580360017","title":"Nuvectis Pharma reports third quarter net loss of $7.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580360017","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580360017?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:30","pubTimestamp":1762259427,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc. reported cash and cash equivalents of $35.4 million as of September 30, 2025, up from $18.5 million at the end of 2024, primarily due to a public offering in February 2025 and the use of its At-the-Market facility. The company reported a net loss of $7.5 million for the third quarter of 2025, compared to a net loss of $4.2 million for the same period in 2024. The increase in net loss was mainly attributed to a one-time $2.0 million milestone expense for NXP900, $0.7 million related to a clinical drug-drug interaction study, and $1.5 million in non-cash stock-based compensation. Key business developments included the initiation of the NXP900 Phase 1b program as a single agent, completion of the Phase 1a dose escalation study, and the successful completion of a clinical drug-drug interaction study in healthy volunteers. The company expects its cash runway to support operations into the third quarter of 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL5rpF2Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","BK4588","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","NVCT"],"gpt_icon":0},{"id":"2580736064","title":"Nuvectis Pharma Q3 Net Income USD -7.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580736064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580736064?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:30","pubTimestamp":1762259401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLX9E5DB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2580739917","title":"Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2580739917","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580739917?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:30","pubTimestamp":1762259400,"startTime":"0","endTime":"0","summary":"NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180214/0/en/Nuvectis-Pharma-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2579146933","title":"Nuvectis Pharma Inc. Files Initial Statement of Beneficial Ownership; Director Juan Sanchez Named as Beneficial Owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2579146933","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579146933?lang=en_us&edition=fundamental","pubTime":"2025-10-31 20:00","pubTimestamp":1761912045,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Juan Sanchez as the beneficial owner in his role as Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDLBK4cw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nuvectis.com","stockEarnings":[{"period":"1week","weight":0.0307},{"period":"1month","weight":0.0331},{"period":"3month","weight":0.4542},{"period":"6month","weight":0.3593},{"period":"1year","weight":0.3807},{"period":"ytd","weight":0.1576}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.130119},{"month":2,"riseRate":0.75,"avgChangeRate":0.143364},{"month":3,"riseRate":0.75,"avgChangeRate":0.129194},{"month":4,"riseRate":0.75,"avgChangeRate":0.042967},{"month":5,"riseRate":0.75,"avgChangeRate":0.205701},{"month":6,"riseRate":0,"avgChangeRate":-0.153353},{"month":7,"riseRate":0.25,"avgChangeRate":-0.099906},{"month":8,"riseRate":0.5,"avgChangeRate":-0.005612},{"month":9,"riseRate":0,"avgChangeRate":-0.100626},{"month":10,"riseRate":0.5,"avgChangeRate":-0.011793},{"month":11,"riseRate":0.25,"avgChangeRate":-0.090389},{"month":12,"riseRate":0.75,"avgChangeRate":0.071233}],"exchange":"NASDAQ","name":"Nuvectis Pharma, Inc.","nameEN":"Nuvectis Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvectis Pharma, Inc.(NVCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvectis Pharma, Inc.,NVCT,Nuvectis Pharma, Inc.股票,Nuvectis Pharma, Inc.股票老虎,Nuvectis Pharma, Inc.股票老虎国际,Nuvectis Pharma, Inc.行情,Nuvectis Pharma, Inc.股票行情,Nuvectis Pharma, Inc.股价,Nuvectis Pharma, Inc.股市,Nuvectis Pharma, Inc.股票价格,Nuvectis Pharma, Inc.股票交易,Nuvectis Pharma, Inc.股票购买,Nuvectis Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvectis Pharma, Inc.(NVCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction